After recent multimillion sales, Roivant (NASDAQ: ROIV) holder plans another

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) received a notice that Eric Venker plans to sell up to 200,000 common shares of Roivant under Rule 144. The planned sale is scheduled for 08/28/2026 on NASDAQ and will be executed via Rockefeller Financial LLC under a Rule 10b5-1 trading plan adopted on 03/28/2025.

Roivant reports that its common shares outstanding were 719,270,385 as of this notice, a baseline figure, not the amount being sold. In the prior three months, Venker has sold additional Roivant shares in three transactions totaling several hundred thousand shares.

Key Figures

Planned shares to be sold: 200,000 common shares Aggregate market value of securities to be sold: $7,147,087.91 Shares outstanding: 719,270,385 common shares +5 more

8 metrics

Planned shares to be sold 200,000 common shares Securities to be sold on 08/28/2026 under Rule 144

Aggregate market value of securities to be sold $7,147,087.91 Value associated with 200,000 shares listed for 08/28/2026 sale

Shares outstanding 719,270,385 common shares Roivant common shares outstanding as referenced in the notice

Sale on 06/24/2026 200,000 shares for $6,631,659.08 Common shares sold during past 3 months by Eric Venker

Sale on 07/27/2026 200,000 shares for $6,989,924.05 Common shares sold during past 3 months by Eric Venker

Sale on 08/20/2026 13,909 shares for $512,407.56 Common shares sold during past 3 months by Eric Venker

Trading plan adoption date 03/28/2025 Date Rule 10b5-1 trading plan was adopted

Planned sale date 08/28/2026 Date listed for intended Rule 144 sale of 200,000 shares

Key Terms

Rule 144, Rule 10b5-1 trading plan, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Rule 10b5-1 trading plan regulatory

"will be sold pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

attorney-in-fact regulatory

"as attorney-in-fact for Venker Eric"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing mean for Roivant Sciences Ltd. (ROIV)?

The filing states that Eric Venker intends to sell up to 200,000 Roivant common shares under Rule 144 on or after 08/28/2026, pursuant to a Rule 10b5-1 trading plan adopted on 03/28/2025.

How many ROIV shares is Eric Venker planning to sell in this notice?

The notice covers up to 200,000 common shares of Roivant Sciences Ltd., with an aggregate market value shown as $7,147,087.91 for the securities to be sold on 08/28/2026.

What Roivant Sciences Ltd. (ROIV) shares has Eric Venker sold in the last 3 months?

Over the past three months, the filing lists sales of 200,000 shares on 06/24/2026, 200,000 shares on 07/27/2026, and 13,909 shares on 08/20/2026, for total proceeds of $6,631,659.08, $6,989,924.05, and $512,407.56, respectively.

How many Roivant (ROIV) shares are outstanding according to this filing?

The securities information section states that Roivant Sciences Ltd. had 719,270,385 common shares outstanding. This is given as a context figure and is not the amount being sold under this Form 144 notice.

Is the planned ROIV sale under a Rule 10b5-1 trading plan?

Yes. The remarks state that the shares reported will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, Eric Venker, on 03/28/2025.

Who is executing the planned sale of Roivant (ROIV) shares?

The securities information lists Rockefeller Financial LLC as the broker, and the notice is signed by Carmen Zamores as a duly authorized representative of National Financial Services LLC, acting as attorney-in-fact for Eric Venker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:34 PM Accepted by SEC EDGAR 08/28/2026 - 04:33 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Roivant Sciences Ltd.
SEC File Number	001-40782
Address of Issuer	7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB
Phone	441-295-5950
Name of Person for Whose Account the Securities are To Be Sold	Venker Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	200000	7147087.91	719270385	08/28/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	08/28/2026	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd.			200000	08/28/2026	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	06/24/2026	200000	6631659.08
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway, London X0 SW1H0DB	Common Shares	07/27/2026	200000	6989924.05
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway, London X0 SW1H0DB	Common Shares	08/20/2026	13909	512407.56

144: Remarks and Signature

Remarks	The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/28/2025.
Date of Notice	08/28/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/28/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Venker Eric
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)